Beyond Biotech - the podcast from Labiotech

• [Rebroadcast] How AI immune system mapping can boost drug discovery

  We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week!Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. In this week’s conversation, Noam Solomon, CEO and co-founder of Immunai, covers the data gap in drug discovery and how machine learning (ML) can solve it, how to de-risk early-stage drug discovery, predictions for AI, and more.00:49-01:13: About Immunai01:13-01:45: Why map the immune system?01:45-02:44: Are you taking a step back to study the problem in order to move forward?02:44-03:49: How difficult is it to map the immune system?03:49-05:29: What is your AMICA platform?05:29-07:24: Where does your data come from?07:24-09:09: How do you account for differences between patients?09:09-11:35: What are the biggest challenges to drug development?11:35-14:07: How can AI improve drug development?14:07-14:55: Will AI advances speed up drug development?14:55-16:06: Is the use of AI applicable in all diseases and conditions?16:06-17:48: What sets your approach apart from other companies using AI?17:48-18:54: What partnerships does Immunai have?18:54-20:24: What are pharma companies looking for from Immunai?20:24-23:17: How can AI help with clinical trials?23:17-24:32: Can AI help with preventative care?24:32-26:30: Google Maps for the immune system26:30-27:18: What will we see from AI in drug discovery in the short term?27:18-28:06: What are the next steps for Immunai?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  28:53
• The TCR-T cell therapies of tomorrow

  Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1.The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date.On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products and partnerships with EmendoBio and Shinobi Therapeutics.00:43-02:10: About Anocca 02:10-04:16: About TCR-T cell therapies and their use in treatments04:16-06:02: Anocca’s approach to T-cell biology, cutting-edge biotechnologies and integrated software06:02-07:58: A different approach to other cell and gene therapy companies07:58-09:16: Facing challenges09:16-10:48: Addressing conditions and diseases10:48-11:54: Pancreatic cancer11:54-13:40: What represents success for Anocca?13:40-14:09: What is VIDAR-1?14:09-16:08: Partnerships16:08-18:05: Scaling up and addressing costs18:05-20:07: How is TCR-T therapy evolving?20:07-23:11: The impact of artificial intelligence23:11-25:16: Anocca timeline25:16-25:57: Closing comments  `Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  26:42
• Can RNA drugs solve the obesity epidemic?

  Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment.Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. By enhancing energy expenditure through white-to-brown adipose tissue conversion while preserving muscle mass, RES-010 is positioned as an ideal standalone therapy or a synergistic option for long-term weight management.The company recently initiated a phase 1 study in December 2024 for RES-010 in healthy and obese subjects, and they also secured an equity investment from Sanofi in October 2024.To talk about ways to tackle obesity, and Resalis’ approach, our guest on the podcast this week is Alessandro Toniolo, CEO of Resalis Therapeutics.00:57-05:06: About Resalis Therapeutics05:06-08:59: Issues of obesity08:59-13:20: Companies working on obesity treatments13:20-15:34: Does suppressing appetite affect nutrition?15:34-17:49: Introduction of new obesity treatments17:49-21:33: Approaches other than appetite suppression21:33-22:38: RES-010 mode of action22:38-24:04: Administration methods24:04-25:11: Clinical trials25:11-26:38: Resalis’ pipeline26:38-28:08: Next steps for Resalis28:08-28:36: Effect of obesity on other parts of the body28:36-29:06: Final comments `Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  29:56
• Reversing cancer mechanisms to fight back against solid tumors

  CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation, proliferation and Interferon-γ signature induction. Visugromab has demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients, as highlighted in its recent Nature publication and interim clinical data. This week we have a conversation with Eugen Leo, chief medical officer at CatalYm.01:30-03:38: About CatalYm03:38-06:59: Solid tumors and also why they are hard to treat06:59-09:04: Current treatments for solid tumors09:04-10:47: What is immunotherapy resistance?10:47-12:23: What is visugromab?12:23-13:32: CatalYm’s clinical development program13:32-15:12: What represents success for patients using visugromab?15:12-17:50: Other treatment options being developed17:50-19:50: CatalYm’s pipeline and the futureThis week’s podcast was sponsored by TCR Solutions.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  21:24
• Targeting the dark genome to develop new therapies to fight obesity

  In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity.The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark GenomeThis week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’00:55-03:47: About Haya Therapeutics03:47-06:37: What is the dark genome?06:37-09:29: What is the connection between lncRNA and disease?09:30-13:22: How can disease be addressed via the dark genome?13:22-16:45: Which diseases are you tackling?16:45-18:02: What is the EchoHAYA platform?18:02-21:07: How does your lead candidate, HTX-001, work?21:07-22:00: Is the objective stopping fibrosis or reversing it?22:00-23:41: Other companies in the field23:41-24:52: Working with Eli Lilly24:52-27:15: A new frontier in medicine?27:15-28:43: Cost effectiveness28:43-30:07: Clinical trials30:07-31:48: Applications to other diseasesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  32:32

Więcej Wiadomości podcastów

Trendy w podcaście Wiadomości

O Beyond Biotech - the podcast from Labiotech